Harvard Cash Flow To Debt Ratio from 2010 to 2024

HBIO Stock  USD 2.20  0.01  0.46%   
Harvard Bioscience Cash Flow To Debt Ratio yearly trend continues to be very stable with very little volatility. Cash Flow To Debt Ratio is likely to drop to 0.35. During the period from 2010 to 2024, Harvard Bioscience Cash Flow To Debt Ratio quarterly data regression pattern had sample variance of  0.03 and median of  0.19. View All Fundamentals
 
Cash Flow To Debt Ratio  
First Reported
2010-12-31
Previous Quarter
0.36936202
Current Value
0.35
Quarterly Volatility
0.17866747
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Harvard Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Harvard Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 M, Interest Expense of 3.8 M or Total Revenue of 96.8 M, as well as many indicators such as Price To Sales Ratio of 1.72, Dividend Yield of 0.0022 or PTB Ratio of 4.65. Harvard financial statements analysis is a perfect complement when working with Harvard Bioscience Valuation or Volatility modules.
  
Check out the analysis of Harvard Bioscience Correlation against competitors.
To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.

Latest Harvard Bioscience's Cash Flow To Debt Ratio Growth Pattern

Below is the plot of the Cash Flow To Debt Ratio of Harvard Bioscience over the last few years. It is Harvard Bioscience's Cash Flow To Debt Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Harvard Bioscience's overall financial position and show how it may be relating to other accounts over time.
Cash Flow To Debt Ratio10 Years Trend
Slightly volatile
   Cash Flow To Debt Ratio   
       Timeline  

Harvard Cash Flow To Debt Ratio Regression Statistics

Arithmetic Mean0.23
Geometric Mean0.15
Coefficient Of Variation78.52
Mean Deviation0.15
Median0.19
Standard Deviation0.18
Sample Variance0.03
Range0.5979
R-Value(0.35)
Mean Square Error0.03
R-Squared0.12
Significance0.20
Slope(0.01)
Total Sum of Squares0.45

Harvard Cash Flow To Debt Ratio History

2024 0.35
2023 0.37
2022 0.0246
2021 0.0261
2020 0.19
2019 0.15
2018 0.0386

About Harvard Bioscience Financial Statements

Harvard Bioscience investors utilize fundamental indicators, such as Cash Flow To Debt Ratio, to predict how Harvard Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cash Flow To Debt Ratio 0.37  0.35 
When determining whether Harvard Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Harvard Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Harvard Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Harvard Bioscience Stock:
Check out the analysis of Harvard Bioscience Correlation against competitors.
To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.80)
Earnings Share
(0.33)
Revenue Per Share
2.258
Quarterly Revenue Growth
(0.13)
Return On Assets
(0.02)
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.